Andy Hsieh
Stock Analyst at William Blair
(1.22)
# 3,682
Out of 4,981 analysts
12
Total ratings
50%
Success rate
-5.16%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Andy Hsieh
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CRBP Corbus Pharmaceuticals Holdings | Initiates: Outperform | n/a | $9.50 | - | 1 | Feb 28, 2025 | |
| SKYE Skye Bioscience | Initiates: Outperform | n/a | $4.25 | - | 1 | Feb 28, 2025 | |
| ALT Altimmune | Initiates: Market Perform | n/a | $3.64 | - | 1 | Feb 28, 2025 | |
| TERN Terns Pharmaceuticals | Initiates: Market Perform | n/a | $7.23 | - | 1 | Feb 28, 2025 | |
| GPCR Structure Therapeutics | Initiates: Outperform | n/a | $20.91 | - | 1 | Feb 28, 2025 | |
| BIOA BioAge Labs | Initiates: Market Perform | n/a | $4.80 | - | 1 | Feb 28, 2025 | |
| MRSN Mersana Therapeutics | Initiates: Outperform | n/a | $7.14 | - | 1 | Feb 6, 2025 | |
| PYXS Pyxis Oncology | Downgrades: Market Perform | n/a | $1.82 | - | 1 | Nov 21, 2024 | |
| LNTH Lantheus Holdings | Initiates: Outperform | n/a | $52.94 | - | 1 | Sep 29, 2023 | |
| FGEN FibroGen | Downgrades: Market Perform | n/a | $12.03 | - | 2 | Jun 26, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $1.63 | - | 1 | Feb 21, 2023 |
Corbus Pharmaceuticals Holdings
Feb 28, 2025
Initiates: Outperform
Price Target: n/a
Current: $9.50
Upside: -
Skye Bioscience
Feb 28, 2025
Initiates: Outperform
Price Target: n/a
Current: $4.25
Upside: -
Altimmune
Feb 28, 2025
Initiates: Market Perform
Price Target: n/a
Current: $3.64
Upside: -
Terns Pharmaceuticals
Feb 28, 2025
Initiates: Market Perform
Price Target: n/a
Current: $7.23
Upside: -
Structure Therapeutics
Feb 28, 2025
Initiates: Outperform
Price Target: n/a
Current: $20.91
Upside: -
BioAge Labs
Feb 28, 2025
Initiates: Market Perform
Price Target: n/a
Current: $4.80
Upside: -
Mersana Therapeutics
Feb 6, 2025
Initiates: Outperform
Price Target: n/a
Current: $7.14
Upside: -
Pyxis Oncology
Nov 21, 2024
Downgrades: Market Perform
Price Target: n/a
Current: $1.82
Upside: -
Lantheus Holdings
Sep 29, 2023
Initiates: Outperform
Price Target: n/a
Current: $52.94
Upside: -
FibroGen
Jun 26, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $12.03
Upside: -
Feb 21, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $1.63
Upside: -